Moderna, Inc. at Morgan Stanley Global Healthcare Conference Transcript
Thanks for joining us, everybody. I'm Terence Flynn, Morgan Stanley's US biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Very pleased to be hosting Moderna this morning. From the company, we have Stephen Hoge, the company's President. Stephen, thanks so much for being here. Really enjoy an opportunity to get to speak with you today.
Questions & Answers
I guess, first, what I wanted to start off with is INT program is front and center. Congratulations on the positive Phase III adjuvant melanoma data. So maybe just talk to us about implications of that data for the broader strategy at Moderna in terms of what does mean for additional indications. What does this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
